Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04028960 · ClinicalTrials.gov registry record · Phase 2
IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase
A Phase 2 study, sponsored by HealthPartners Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04028960 is a Phase 2 study that was terminated before completion, run by HealthPartners Institute. The registered enrollment target is 4 participants.
The verdict
NCT04028960, a Phase 2 study, was terminated before completion, sponsored by HealthPartners Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how Humulin-R regular insulin affects the body's ability to feel low blood sugar (hypoglycemia) when delivered intranasally compared to placebo in subjects with Type 1 Diabetes (T1D) with hypoglycemia awareness. The study will use continuous glucose monitoring (CGM) to collect this information. The study drug or placebo will be administered using an intranasal device.
Interventions
- DRUG Regular insulin (Humulin-R), intranasal route
- DEVICE SipNose intranasal device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-10-23 |
| Est. Completion | 2020-04-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04028960
The ClinicalTrials.gov registry entry for NCT04028960 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regular insulin (Humulin-R), intranasal route is the first listed.
NCT04028960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04028960 about?
NCT04028960 is a clinical study titled "IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase". The purpose of this study is to determine how Humulin-R regular insulin affects the body's ability to feel low blood sugar (hypoglycemia) when delivered intranasally compared to placebo in subjects with Type 1 Diabetes (T1D) with hypoglycemia awareness. The study will use continuous glucose monitori...
What is the current status of trial NCT04028960?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2019-10-23. Estimated completion is 2020-04-08.
What interventions are being tested in trial NCT04028960?
The interventions under investigation include: Regular insulin (Humulin-R), intranasal route (DRUG), SipNose intranasal device (DEVICE).
Who is sponsoring clinical trial NCT04028960?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.